Takeda Pharma launches Rare Disease Therapies in India
Under lysosomal storage disorders, India has been recording the prevalence of Hunter syndrome, Gaucher disease and Fabry disease, Takeda said in a statement.
New Delhi: Takeda Pharmaceutical Company recently said that it has launched an enzyme replacement therapy portfolio for lysosomal storage disorders (LSD) in India, expanding its range of rare disease therapies in the country.
Under lysosomal storage disorders, India has been recording the prevalence of Hunter syndrome, Gaucher disease and Fabry disease, Takeda said in a statement.
Read Also: Novartis buys Takeda dry eye drug Xiidrafor for $3.4 billion
To address these, Takeda brings to the market Idursulfase for Hunter syndrome, Velaglucerase Alpha for Gaucher disease and Agalsidase Alfa for Fabry disease, it added.
"At Takeda, we are committed to patient care by developing innovative new medicines and making existing medicines more readily available," Takeda India Country Head Vineet Singhal said.
Japan-based Takeda focuses on research and development efforts on four therapeutic areas: oncology, gastroenterology (GI), neuroscience and rare diseases.
Read Also: Undeterred by Sanofi stumble, Takeda takes similar path with dengue shot
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd